CARS1 (Cysteinyl-tRNA Synthetase 1) encodes an essential enzyme responsible for the attachment of the amino acid cysteine to its cognate tRNA molecules. This catalytic activity, termed aminoacylation, is fundamental to protein synthesis and represents one of the most essential enzymatic reactions in all living organisms. Beyond this canonical role in translation, CARS1, like many other aminoacyl-tRNA synthetases, exhibits extra-translational functions including roles in RNA processing, mitochondrial iron-sulfur cluster assembly, and immune regulation. This page provides comprehensive information about CARS1's structure, function, expression patterns, and relevance to neurodegenerative diseases.
**Symbol:** CARS1 (formerly CARS)
**Full Name:** Cysteinyl-tRNA Synthetase 1
**Chromosomal Location:** 11p15.5
**NCBI Gene ID:** [8438](https://www.ncbi.nlm.nih.gov/gene/8438)
**OMIM:** [601299](https://www.omim.org/entry/601299)
**Ensembl ID:** [ENSG00000198055](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198055)
**UniProt ID:** [P49589](https://www.uniprot.org/uniprotkb/P49589)
**Gene Type:** Protein coding
**Protein Length:** 750 amino acids
**Associated Diseases:** Mitochondrial disorders, Friedreich ataxia, Hepatic failure
CARS1 belongs to the family of aminoacyl-tRNA synthetases (ARS), which consists of 37 enzymes in humans (one for each amino acid, with some having multiple isoforms):
| ARS |
Location |
Associated Diseases |
| CARS1 |
Cytosol + Mitochondria |
Mitochondrial disease |
| YARS1 |
Cytosol |
Dominant Charcot-Marie-Tooth |
| GARS1 |
Cytosol + Mitochondria |
Charcot-Marie-Tooth, CMT2D |
| AARS1 |
Cytosol |
Charcot-Marie-Tooth, CMT2N |
| HARS1 |
Cytosol + Mitochondria |
Charcot-Marie-Tooth |
| MARS2 |
Mitochondria |
Spastic ataxia |
| RARS2 |
Mitochondria |
Pontocerebellar hypoplasia |
| PARS1 |
Mitochondria |
Mitochondrial disease |
The CARS1 enzyme is unique among ARS family members in its association with multiple cellular compartments and functions.
¶ Protein Structure and Function
CARS1 has a complex, multi-domain structure:
- N-terminal domain: Contains appended domains for non-canonical functions
- Core catalytic domain: The conserved Rossmann-fold catalyzes aminoacylation
- ** anticodon-binding domain:** Recognizes the tRNA anticodon
- C-terminal domain: Additional regulatory and interaction motifs
The protein contains:
- Active site for ATP-dependent cysteine activation
- Zinc finger motif for tRNA binding
- Nuclear localization signals
- Mitochondrial targeting sequence (alternatively spliced)
The aminoacylation reaction proceeds through two steps:
-
Cysteine activation:
Cysteine + ATP → Cys-AMP + PPi
-
tRNA charging:
Cys-AMP + tRNA^Cys → Cys-tRNA^Cys + AMP
This reaction is essential for decoding the genetic code during translation.
CARS1 undergoes alternative splicing generating multiple isoforms:
- Isoform 1: Full-length (750 aa) with mitochondrial targeting
- Isoform 2: Cytosolic form without mitochondrial targeting
- Isoform 3: Tissue-specific variants
CARS1 is expressed ubiquitously with highest levels in:
| Tissue |
Expression Level |
Functional Implications |
| Heart |
Very high |
High metabolic demand |
| Skeletal muscle |
High |
Protein synthesis |
| Brain |
High |
Neuronal function |
| Liver |
High |
Metabolic functions |
| Kidney |
Moderate |
Metabolic functions |
| Lung |
Moderate |
Metabolic functions |
Within the brain, CARS1 shows region-specific expression:
- Cerebral cortex: High expression in pyramidal neurons
- Hippocampus: High in CA1-CA3 neurons and dentate gyrus
- Cerebellum: High in Purkinje cells
- Brainstem: Moderate expression
- Spinal cord: Moderate in motor neurons
CARS1 localizes to multiple compartments:
- Cytosol: Primary location for translation
- Mitochondria: Import via targeting sequence
- Nucleus: Present in some cell types
- Stress granules: During stress conditions
This distribution enables both canonical and non-canonical functions.
The primary function of CARS1 is ensuring accurate translation:
- Cys-tRNA production: Supplies charged tRNA for ribosomal protein synthesis
- Quality control: Rejects incorrect amino acids
- Reading frame maintenance: Ensures proper decoding
- Codon recognition: Recognizes specific tRNA anticodons
This function is essential for all protein synthesis in the cell.
CARS1 participates in iron-sulfur (Fe-S) cluster assembly:
- Interacts with the CIA (Cytosolic Iron-sulfur cluster Assembly) machinery
- Required for transfer of sulfur atoms
- Essential for Fe-S cluster maturation
- Critical for numerous enzyme functions
Some ARS enzymes participate in RNA metabolism:
- Splicing factor recruitment
- RNA modification
- microRNA processing
CARS1 can be secreted and functions as an immune modulator:
- Extracellular functions as cytokine-like molecule
- Autoantibody target in some autoimmune conditions
- Wound healing and tissue repair
CARS1 has a special connection to Friedreich ataxia:
- Frataxin (FXN) is deficient in Friedreich ataxia
- CARS1 interacts with frataxin in Fe-S cluster assembly
- Impaired function contributes to mitochondrial dysfunction
- May represent therapeutic target
- Mitochondrial iron accumulation
- Impaired Fe-S cluster enzymes
- Oxidative stress
- Progressive neurodegeneration
Mutations in CARS-related genes cause CMT:
- GARS1 (glycyl-tRNA synthetase) mutations cause CMT2D
- CARS1 variants may contribute to peripheral neuropathy
- Mechanisms involve toxic gain-of-function
- Axonal degeneration
CARS1 mutations can cause severe disease:
- Subacute necrotizing encephalomyelopathy
- Severe neurological deterioration
- Bilateral lesions in brainstem
- Early infantile onset
- Combined oxidative phosphorylation deficiencies
- Mitochondrial translation defects
- Seizures and developmental regression
Connections to ALS include:
- Mitochondrial dysfunction in motor neurons
- Impaired protein homeostasis
- Stress granule formation
- RNA metabolism alterations
Potential roles in AD:
- Mitochondrial dysfunction is a hallmark
- Protein synthesis changes in early AD
- CARS may have protective roles
- Could affect amyloid processing
CARS1 represents a therapeutic target:
- Enzyme activators: Enhance aminoacylation efficiency
- Fe-S cluster modulators: Improve mitochondrial function
- Protein homeostasis enhancers: Support translation
- Gene therapy approaches: Viral delivery
Developing CARS1-targeted therapies:
- Essential enzyme function
- Multiple isoforms and locations
- Blood-brain barrier penetration needed
- Potential for compensatory mechanisms
¶ Interactions and Pathway Membership
| Partner |
Interaction |
Function |
| FXN |
Frataxin |
Fe-S cluster assembly |
| ISCU |
Iron-sulfur cluster scaffold |
Fe-S assembly |
| NFU1 |
Fe-S cluster transfer |
Fe-S assembly |
| tRNA^Cys |
Substrate |
Protein synthesis |
| ABCB7 |
Mitochondrial transporter |
Fe-S assembly |
| EEF1A1 |
Translation factor |
Protein synthesis |
CARS1 participates in:
- Protein synthesis in cytoplasm (GO:0006412)
- Mitochondrial translation (GO:0032543)
- Iron-sulfur cluster assembly (GO:0016226)
- Immune response (GO:0006955)
- tRNA aminoacylation (GO:0006420)
- GARS1 — glycyl-tRNA synthetase
- YARS1 — tyrosyl-tRNA synthetase
- AARS1 — alanyl-tRNA synthetase
- FXN — frataxin
- ISCU — Fe-S cluster scaffold
- MT-CYB — mitochondrial complex III
The study of CARS1 has evolved significantly:
- 1990s: Cloning and initial characterization
- 2000s: Understanding of non-canonical functions
- 2010s: Recognition in mitochondrial disease
- 2020s: Therapeutic targeting approaches
Historical context shows progression from basic biochemistry to disease understanding.